Treosulfan-Based Conditioning Regimen for Second Allograft in Patients with Myelofibrosis.

myelofibrosis second allogeneic transplant stem cell transplantation treosulfan

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
23 Oct 2020
Historique:
received: 31 08 2020
revised: 15 10 2020
accepted: 21 10 2020
entrez: 29 10 2020
pubmed: 30 10 2020
medline: 30 10 2020
Statut: epublish

Résumé

Relapse after allogeneic hematopoietic stem cell transplantation (AHSCT) in myelofibrosis (MF) patients remains as a significant issue despite advances in transplantation procedures and significant prolongation in survival. Second AHSCT is a potential treatment option but associated with high treatment-related mortality and novel less toxic conditioning regimens are needed. In 33 MF patients with relapse after AHSCT and failure to donor lymphocyte infusion (DLI) we investigated treosulfan (36-42 g/m

Identifiants

pubmed: 33114179
pii: cancers12113098
doi: 10.3390/cancers12113098
pmc: PMC7690833
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Biol Blood Marrow Transplant. 2018 Apr;24(4):751-757
pubmed: 29247780
Biol Blood Marrow Transplant. 2016 Jul;22(7):1206-1211
pubmed: 26970380
Br J Haematol. 2018 Aug;182(3):418-422
pubmed: 29808926
Biol Blood Marrow Transplant. 2014 Jan;20(1):89-97
pubmed: 24161923
Leuk Lymphoma. 2007 Dec;48(12):2352-9
pubmed: 18067010
Br J Haematol. 2012 Oct;159(2):172-81
pubmed: 22909192
Bone Marrow Transplant. 2009 Sep;44(5):317-20
pubmed: 19234505
Bone Marrow Transplant. 2019 Feb;54(2):204-211
pubmed: 29795431
Haematologica. 2008 Oct;93(10):1514-22
pubmed: 18728030
Bone Marrow Transplant. 2006 Feb;37(4):339-44
pubmed: 16415898
Blood. 2009 Dec 17;114(26):5264-70
pubmed: 19812383
Haematologica. 2019 Sep;104(9):1782-1788
pubmed: 30733269
Bone Marrow Transplant. 2016 Sep;51(9):1223-7
pubmed: 27088376
J Clin Oncol. 2011 Feb 20;29(6):761-70
pubmed: 21205761
Lancet Haematol. 2020 Jan;7(1):e28-e39
pubmed: 31606445
Bone Marrow Transplant. 2012 Jan;47(1):5-14
pubmed: 21478921
Bone Marrow Transplant. 1995 Jun;15(6):825-8
pubmed: 7581076
Hematol Oncol. 2016 Sep;34(3):154-60
pubmed: 25469485
Blood. 2005 May 15;105(10):4115-9
pubmed: 15671439
Am J Hematol. 2004 Oct;77(2):204-5
pubmed: 15389913
Biol Blood Marrow Transplant. 2015 Nov;21(11):1883-7
pubmed: 26371371
Blood. 2009 Feb 19;113(8):1866-8
pubmed: 19228938
Biol Blood Marrow Transplant. 2015 Mar;21(3):389-401.e1
pubmed: 25529383

Auteurs

Isik Kaygusuz Atagunduz (IK)

Hematology Department, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.
Hematology Department, Marmara University Pendik Training and Research Hospital, 34899 Istanbul, Turkey.

Evgeny Klyuchnikov (E)

Hematology Department, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.

Christine Wolschke (C)

Hematology Department, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.

Dietlinde Janson (D)

Hematology Department, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.

Silke Heidenreich (S)

Hematology Department, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.

Maximilian Christopeit (M)

Hematology Department, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.

Francis Ayuk (F)

Hematology Department, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.

Nicolaus Kröger (N)

Hematology Department, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.

Classifications MeSH